MedTrace Logo

Study to Compare Different Formulations of AZD3355

NCT00688402 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2010-12-03

No results posted yet for this study

Summary

The purpose of the study is to compare different formulations of AZD3355 in regard to possible adverse events such as sensations of numbness, tinglings and heat in the skin.

Conditions

  • Gastroesophageal Reflux Disease

Interventions

DRUG

AZD3355

Single dose

Sponsors & Collaborators

Principal Investigators

  • Eva Ersdal, PhD · AstraZeneca R&D, Mölndal, Sweden

  • Aslak Rautio, MD · Quintiles Hermelinen, Varvsgatan 53, SE-972 33 Luleå, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Sweden

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00688402 on ClinicalTrials.gov